4.46
4.46 (0%)
As of Feb 14, 2025
Adverum Biotechnologies, Inc. [ADVM]
Source:
Company Overview
Adverum Biotechnologies, Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases. We discover and develop gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein.
| Country | United States |
| Headquarters | redwood city, california |
| Phone Number | (650) 656-9323 |
| Industry | manufacturing |
| CEO | Laurent Fischer |
| Website | www.adverum.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $0 |
| Operating Profit | $-20.9 |
| Net Income | $-18.5 |
| Net Cash | $52.3 |
Profit Ratios
| Gross Margin | $0 |
| Operating Margin | |
| Profit as % of Revenues | |
| Profit as % of Assets | -14.6% |
| Profit as % of Stockholder Equity | -11% |
Management Effectiveness
| Return on Equity | -11% |
| Return on Assets | -7.3% |
| Turnover Ratio | |
| EBITA | $-20.9 |
Balance Sheet and Cash Flow Measures
| Total Assets | $253.8 |
| Total Liabilities | $85.8 |
| Operating Cash Flow | $-43.1 |
| Investing Cash Flow | $-24.4 |
| Financing Cash Flow | $119.8 |
